trial · primary record
Biospecimen Collection
Ann Arbor Stage III Diffuse Large B-Cell Lymphoma
| Phase | Phase 2, Phase 3 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 422 |
| Primary completion | 2027-03-01 |
| Primary endpoint | Excess toxicity as a result of adding oral azacitidine (CC-486) to reduced dose rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisone (R-miniCHOP) (Safety run-in) |
| Registry ID | NCT04799275 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:31:56.591Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT04799275
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.